Eicosapentaenoic acid ethyl ester

• CAT Number: I005170
• CAS Number: 86227-47-6
• Molecular Formula: C22H34O2
• Molecular Weight: 330.51
• Purity: ≥95%
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IUPAC Name: ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
• InChI: InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-
• InChIKey: SSQPWTVBQMWLSZ-AAQCHOMXSA-N
• SMILES: CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC

Eicosapentaenoic acid ethyl ester（Cat No.:I005170） is a compound derived from eicosapentaenoic acid (EPA), an omega-3 fatty acid found in certain fish oils. It is commonly used as an omega-3 fatty acid agent due to its potential health benefits. Eicosapentaenoic acid ethyl ester has been studied for its anti-inflammatory properties, cardiovascular benefits, and potential in managing certain conditions such as hypertriglyceridemia and rheumatoid arthritis. It is often consumed as a dietary supplement or incorporated into pharmaceutical formulations to support overall health and well-being.

Reference

1:Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA.Am J Cardiol. 2017 Feb 1;119(3):397-403. doi: 10.1016/j.amjcard.2016.10.027. Epub 2016 Nov 1. PMID: 27939227 Free Article2:Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Braeckman RA, Stirtan WG, Soni PN, Juliano RA.Atherosclerosis. 2016 Oct;253:81-87. doi: 10.1016/j.atherosclerosis.2016.08.005. Epub 2016 Aug 20. PMID: 27596132 Free Article3:Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA.J Clin Lipidol. 2016 May-Jun;10(3):635-645.e1. doi: 10.1016/j.jacl.2016.02.008. Epub 2016 Feb 23. PMID: 27206952 Free Article4:Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects. Braeckman RA, Stirtan WG, Soni PN.Clin Pharmacol Drug Dev. 2015 Mar;4(2):143-148. Epub 2014 Dec 3. PMID: 26097794 Free PMC Article5:Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA.Metab Syndr Relat Disord. 2015 Aug;13(6):239-47. doi: 10.1089/met.2014.0137. Epub 2015 Apr 20. PMID: 25893544 6:Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Braeckman RA, Stirtan WG, Soni PN.Clin Drug Investig. 2015 Jan;35(1):45-51. doi: 10.1007/s40261-014-0252-8. PMID: 25471740 Free PMC Article7:Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Braeckman RA, Stirtan WG, Soni PN.Drugs R D. 2014 Sep;14(3):159-64. doi: 10.1007/s40268-014-0053-9. PMID: 24973042 Free PMC Article8:A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Jacobson TA.Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-95. doi: 10.1586/erc.12.56. PMID: 22894624 9:Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20. PMID: 22819432 10:Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN.Am J Cardiol. 2011 Sep 1;108(5):682-90. doi: 10.1016/j.amjcard.2011.04.015. Epub 2011 Jun 16. PMID: 21683321